Drug Approvals International

All about Drugs Live by Dr Anthony Melvin Crasto

Menu
  • Home
  • About Drug Approvals International
  • ABOUT ME
  • Contact me
  • Drug information Portal
  • FAQ
  • Message me
  • News
  • Testimonials

Drug information Portal

It's only fair to share...Flattr the authorPin on PinterestEmail this to someone
Buffer this pageDigg thisShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInShare on YummlyShare on VKShare on RedditShare on StumbleUponPrint this pageShare on Tumblr

 

Drug information Portal

https://druginfo.nlm.nih.gov/drugportal/

It's only fair to share...Flattr the authorPin on PinterestEmail this to someone
Buffer this pageDigg thisShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInShare on YummlyShare on VKShare on RedditShare on StumbleUponPrint this pageShare on Tumblr

  • Search this site

  • Get email of posts

    Add email in subscribe box and get email of posts
    Name
    Email *
  • Menu

    • About Drug Approvals International
    • Contact me
    • FAQ
    • Message me
    • Testimonials
    • News
    • Drug information Portal
    • ABOUT ME
  • Meta

    • Register
    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
  • Archives

  • Subscribe to Drug Approvals International

    Get blog posts in your Mail box

  • Categories

    • 2020 APPROVALS
    • Accelerated approval
    • Acute Hepatic Porphyria
    • alzheimers
    • ANAESTHETIC
    • anaesthetics
    • ANALGESIC
    • ANTI ACNE
    • anti bacterial
    • ANTI DIABETIS
    • ANTI FUNGAL
    • ANTI HBV
    • ANTI INFLAMOTORY
    • ANTI tuberculostatic
    • ANTI VIRAL
    • ANTIBIOTICS
    • ANTICONVULSANT
    • ANTIDEPRESSANT
    • ANTIEMETIC
    • Antiglaucoma
    • Antihypertensives
    • ANTIMALARIALS
    • Antineoplastic
    • ANTIOBESITY
    • Antispasmodic
    • ANTITUSSIVE
    • ANTIULCERATIVE
    • APPROVALS 2020
    • APPROVALS 2021
    • APPROVALS 2022
    • APPROVALS 2023
    • APPROVALS 2024
    • approvals 2024, fda 2024
    • APPROVALS 2025
    • AUSTRALIA 2021
    • AWARD
    • Ayurveda
    • Biosimilars
    • bone marrow disorder
    • Breakthrough Therapy Designations
    • Cancer
    • CHINA
    • CHINA 2011
    • CHINA 2012
    • CHINA 2018
    • china 2019
    • CHINA 2023
    • Conference
    • CORONAVIRUS
    • Coronavirus disease
    • COVID 19
    • CYSTIC FIBRIOSIS
    • DENGUE
    • DIABETES
    • drug
    • Drugs for Neglected Diseases initiative DNDi
    • Duchenne Muscular Dystrophy
    • EMA 2019
    • EU 2003
    • EU 2012
    • EU 2014
    • EU 2015
    • EU 2016
    • EU 2017
    • EU 2018
    • EU 2020
    • EU 2021
    • EU 2022
    • Fast track
    • FDA 2009
    • FDA 2010
    • FDA 2011
    • FDA 2012
    • FDA 2013
    • FDA 2014
    • FDA 2015
    • FDA 2016
    • FDA 2017
    • fda 2018
    • FDA 2019
    • FDA 2020
    • FDA 2021
    • FDA 2022
    • FDA 2023
    • FDA 2024
    • FDA 2025
    • female sexual dysfunction
    • Flow chemistry
    • FLOW SYNTHESIS
    • GAIN
    • Gastric Proton Pump Inhibitor
    • Generics
    • GLIPTIN
    • GOUT
    • Green chemistry
    • hepatitis C viral infections
    • HIV
    • HORMONE
    • hyperuricemia
    • HYPNOTIC
    • Idiopathic pulmonary fibrosis
    • impurity
    • IND 2017
    • INDIA 2018
    • INDIA 2020
    • INDIA 2021
    • INDIA 2022
    • JAPAN 2009
    • JAPAN 2012
    • JAPAN 2013
    • JAPAN 2014
    • JAPAN 2015
    • JAPAN 2016
    • JAPAN 2018
    • JAPAN 2019
    • JAPAN 2020
    • japan 2021
    • JAPAN 2022
    • KOREA 2012
    • korea 2019
    • lactams
    • MACIMORELIN ACETATE
    • MACROLIDES
    • MALARIA
    • migraine
    • MONKEY POX
    • Monoclonal antibodies
    • NATURAL PRODUCTS
    • obesity
    • OCCULAR
    • ocular hypertension
    • organic chemistry
    • orphan drug
    • Orphan Drug Status
    • OSTEOARTHRITIS
    • PAIN
    • Patent
    • peptide
    • PHASE 1
    • Phase 2
    • PHASE 3
    • Plaque psoriasis
    • Preclinical
    • PRIME designation
    • Priority review
    • process
    • Psoriasis
    • Qualified Infectious Disease Product designation
    • radio labelled
    • RADIOACTIVE AGENT
    • Regulatory
    • Rheumatoid arthritis
    • RNA ingredient BNT-162B2
    • SCHELORING AGENT
    • Sclerosing Agent
    • SEADTIVE
    • siRNA
    • spectroscopy
    • synthesis
    • Tropical Disease Priority Review Voucher
    • Uncategorized
    • vaccines
    • veterinary
    • VIRUS
    • vitamins
    • x ray contrast agent
  • Recent Posts

    • Eclitasertib
    • Perfluorhexyloctane
    • DIMDAZENIL
    • Digadoglucitol
    • Tofersen
    • Deupsilocin
    • Demannose
    • Leniolisib
    • DAZDOTUFTIDE
    • Rezafungin
  • NEW DRUG APPROVALS

  • FLAGS AND HITS

    Free counters!
  • Search Drug Approvals International

  • Categories

  • Recent Comments

    • Jessica on FOTAGLIPTIN
    • Gaurav Singh on Production of High-Quality Diesel from Biomass Waste Products
    • Leo on Clenbuterol
    • Toby Hoch on Valdetamide
    • Sakshi Modgil on Flow Chemistry in Industrial Scale Organic Synthesis, 17th Jan, 2017 from 9-5pm in Ramada Powai Hotel & Convention Centre, Mumbai, India.
  • Follow Us

  • Asense

Drug Approvals International © 2025

Theme by WP Puzzle

➤